Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are clonal myeloproliferative neoplasms (MPNs) with a high frequency of the 1849G4T mutation in JAK2 referred to as JAK2V617F. How this mutation gives rise to different clinical phenotypes with diverse prognoses is unknown. Expression of JAK2V617F in genetically modified mice correlates with disease features. 1 Some data in humans support this notion. [2] [3] [4] Other mutations, including those in JAK2 exon-12, TET2, MPL, EZH2 and ASXL1 occurs at varying frequency 5 in persons with MPNs Whether these mutations correlate with disease phenotype and/or prognosis is unknown.
Another possible explanation for the diversity of MPNs associated with JAK2V617F is the genetic background on which the mutation occurs. One potential relevant factor is the specific constitutional JAK2 haplotype, designated 46/1 or GGCC, which is correlated with JAK2V617F in cases of European descent. [6] [7] [8] [9] We recently reported that Chinese with PMF have different clinical features than that of Europeans with PMF despite a similar frequency of JAK2V617F. 10 We sought to determine whether the JAK2 46/1 haplotype was also associated with JAK2V617F in Chinese and whether differences in the frequency of this genotype might explain different clinical phenotypes of Chinese and Europeans with PMF and other MPNs.
To accomplish this, we assessed JAK2V617F allele burden and genotyped three 46/1 tagged SNPs in 635 Chinese with PV, ET or PMF (Supplementary Table 1 Accepted article preview online, 22 January 2013; advance online publication, 8 February 2013 Letters to the Editor Bone marrow specimens were collected from subjects at diagnosis. Blood samples were collected from controls. Genomic DNA was extracted using the AxyPrep blood genomic DNA miniprep kit (Axygen Biosciences, Union City, CA, USA, Catalogue No. AP-MN-BL-GDNA-250). JAK2V617F allele burden was determined by allele-specific PCR and subsequently with capillary electrophoresis as described with an estimated sensitivity at 0.2%.
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SNP genotyping of three 46/1 tag SNPs, rs12340895, rs10974944 and rs10118930 (the G-allele, G-allele and T-allele tags the JAK2 46/1 haplotypes) was performed by Taqman assays (Applied Biosystems, Foster City, CA, USA) with the 7500HT realtime PCR instrument using standard protocols. The following assays were used: C_31941696, C_31941686 and C_29908796. We used previously defined criteria to cope with skewed allelic ratio caused by uniparental disomy at JAK2. 6 Both polymorphisms were tested by Hardy-Weinberg equilibrium in subjects and controls. Haplotype phases (computed using expectation-maximization algorithm) and haplotype associations were determined in PLINK. PLINK-derived linkage disequilibrium values were subsequently visualized using Haploview software.
Numerical variables were summarized by median, 95% confidence interval and range. Correlations between sample groups and clinical and laboratory data were calculated with the w 2 and the Fisher exact test for qualitative variables with discrete categories and the Mann-Whitney U-test or Kruskal-Wallis analysis of variance for continuous variables. The nonparametric Spearman rank correlation was used to test for correlation between JAK2V617F allele burden and ordinal clinical variables. Two-tailed P-values o0.05 were considered significant.
JAK2V617F was identified in 396 cases (62%, 95% CI: 59-66%), including cases with PV (90%), ET (59%), PMF (48%), MPN-U (72%) and post-PV and post-ET myelofibrosis (74%). The distributions of JAK2V617F allele burden and quartile values according to JAK2V617F allele burden are shown in Figure 1 . Median JAK2V617F mutant allele ratio in PMF with JAK2V617F (N ¼ 99) was 45% (range, 2-94%). This value is significantly higher than JAK2V617F allele burden in PV (N ¼ 112; 29%; range, 1-86%; Pp0.001) or ET (N ¼ 155; 16%; range, 2-92%; Pp0.001). JAK2V617F allele burden in ET was also significantly less than in PV (Pp0.001). The 46/1 tag SNPs (rs12340895, rs10974944 and rs10118930) were in linkage disequilibrium in the MPN cohort and healthy controls ( Supplementary Figures 1 and 2) . To evaluate the association of JAK2 46/1 haplotype with JAK2V617F, we compared cases with MPN with healthy controls and with Chinese (Han) HapMap controls. We found that allelic variations at these 46/1 tag SNPs were strongly associated with predisposition to JAK2V617F-positive but not -negative MPNs (Table 1) . Frequencies of JAK2 46/1 SNPs were also significantly higher in PV and in JAK2V617F-mutated PMF and ET cases than in controls. In contrast, there was no significant difference in 'G/T' allele distribution between controls and cases with PMF or with ET without JAK2V617F (Table 1) .
To study a possible correlation between JAK2V617F allele burden and rs10974944 genotypes, we divided cases with PV and ET and JAK2V617F into three or four groups according to JAK2V617F allele burden. Even in cases with o25% JAK2V617F burden, we found a significantly higher 46/1 frequency than in controls or as predicted from the Chinese (Han) Hapmap. These data suggest the 46/1 haplotype increased the risk of developing JAK2V617F-mutated PV and ET regardless of JAK2V617F allele burden.
Cases with PMF and JAK2V617F with an allele burden o25 or 26-50% had increased representation of the G allele compared with that of controls (frequencies of 39 and 36%; P40.05). However, compared with the Chinese (Han) HapMap data (N ¼ 82), there was a significantly increased frequency of JAK2 46/1 in cases with PMF and a JAK2V617F allele burden o25% (P ¼ 0.033). The frequency of JAK2 46/1 was also higher in cases with a JAK2V617F allele burden of 26-50% (P ¼ 0.05), consistent with an association of 46/1 haplotype with JAK2V617F in cases with PMF (Supplementary Table 2) .
Clinical correlates of the JAK2 46/1 alleles, especially in the context of JAK2V617F allele burden, are uncertain. The correlation of JAK2V617F allele burden and JAK2 46/1 haplotype with clinical variables were further analyzed. In PV, JAK2 46/1 (G/T)-allele frequencies of SNPs rs10118930, rs10974944 and rs12340895 were 45, 49 and 48%. Homozygosity for the JAK2 46/1 haplotype was more common in women. JAK2 46/1 SNP alleles were also correlated with platelet levels. We found no correlation between JAK2 46/1 tag SNPs and age, hemoglobin concentration, WBCs, hematocrit, LDH level, splenomegaly or thrombosis risk (Supplementary Tables 3-5 ). Using the Spearman rank correlation test for continuous variables, we found JAK2V617F allele burden correlated with age (r ¼ 0.195; P ¼ 0.039; Supplementary Figure 3A) , hematocrit (r ¼ 0.235, P ¼ 0.031, Supplementary  Figure 3B) , WBC (r ¼ 0.298; P ¼ 0.002; Supplementary Figure 3C ) and spleen size (r ¼ 0.307; P ¼ 0.005; Supplementary Figure 3D) but not with LDH level (P ¼ 0.111), hemoglobin concentration (P ¼ 0.169) or platelet level (P ¼ 0.287). JAK2V617F allele burden was also significantly higher in women (P ¼ 0.049) but not Abbreviations: P1, P-value for JAK2 46/1 allele frequency comparisons with that of healthy local controls; P2, P-value for comparison of JAK2 46/1 allele frequency with that of Chinese (Han) Hapmap controls.
Letters to the Editor when there was splenomegaly (P ¼ 0.069). JAK2V617F allele burden was similar between cases with and without thromboembolic events (P ¼ 0.525). When JAK2V617F allele burden was treated as a categorical variable with cohorts of p25%, 425-50% and 450%, there was no longer a significant correlation with hematocrit, WBC, spleen size or gender (Supplementary Table 6 ). Numbers of events for constitutional symptoms, progression to myelofibrosis and blastic transformation were too few to analyze. In ET, JAK2 46/1 (G/T)-allele frequencies of SNPs rs10118930, rs10974944 and rs12340895 were 40, 41 and 41%, respectively. The JAK2 46/1 haplotype was significantly associated with a higher hemoglobin concentration and higher hematocrit and WBCs levels at diagnosis. SNPs genotypes were not significantly correlated with age, gender, other hematological variable, splenomegaly, constitutional symptoms or thromboembolic events (Supplementary Tables 7-9 ). Using the Spearman rank correlation test, we found a significant correlation between JAK2V617F allele burden and age (r ¼ 0.212; P ¼ 0.008; Supplementary Figure 4A) and WBC (r ¼ 0.372; Po ¼ 0.001; Supplementary Figure 4B ). There was no significant correlation between JAK2V617F allele burden and gender, splenomegaly, constitutional symptoms or thromboembolic events during the observation interval. Using the Mann-Whitney U-test, we found a correlation between a 415% JAK2V617F allele burden and age (P ¼ 0.035), WBCs (P ¼ 0.001) and platelet level (P ¼ 0.035). There were no significant differences in gender, splenomegaly, constitutional symptoms or thromboembolic events between these subcohorts. (Supplementary Table 10 ).
In PMF, JAK2 46/1 (G/T)-allele frequencies of SNP rs10118930, rs10974944 and rs12340895 were 35, 38 and 37% respectively. Distributions of age, sex, splenomegaly, constitutional symptoms and blastic transformation were not significantly correlated with 46/1 tag SNPs genotype. Homozygosity for JAK2 46/1 haplotype (TT/GG at rs10118930, rs10974944 and rs12340895) was significantly associated with higher hemoglobin concentration and WBCs at diagnosis. SNPs rs10974944 and rs12340895 genotype were significantly correlated with platelet levels. Homozygosity for the JAK2 46/1 haplotype was more frequent in the low-risk IPSS and DIPSS cohorts than in the higher-risk cohorts (Supplementary  Tables 11-13 ). In the 99 cases with JAK2V617F, there was a significant correlation between mutant allele burden and WBCs level(r ¼ 0.398; P ¼ 0.010; supplementary Figure 5 ), but not other hematologic variables, age, spleen size or lactate dehydrogenase (LDH) level. We also found no significant correlation between JAK2V617F allele burden and gender, splenomegaly, constitutional symptoms, IPSS or DIPSS risk category or risk of blastic transformation. Subjects with a JAK2V617F allele burden X50% had significantly higher WBC levels (P ¼ 0.010) than those with a lower JAK2V617F allele burden. The conclusion was similar when JAK2V617F allele burden was analyzed as a categorical variable (Supplementary Table 14) .
In summary, our data support the notion that JAK2V617F allele burden correlates with clinical phenotype in MPNs. Our data also show that the germline JAK2 46/1 haplotype predisposes to acquisition of JAK2V61F in Chinese similar to persons of European descent, [12] [13] [14] [15] indicating that the underlying basis has a relatively old evolutionary origin. Furthermore, JAK2 46/1 may affect their clinical phenotype and/or prognosis in Chinese. What remains uncertain is why the phenotype of PMF in Chinese differs so substantially from that in persons of European descent. The explanation does not appear to be due to the background 46/1 haplotype and therefore other mechanisms, presumably genetic or epigenetic, must operate. These possibilities are under investigation.
